- Home
- CVKD vs CALC Comparison
CVKD vs CALC Comparison
Compare CVKD & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- CALC
- Stock Information
- Founded
- CVKD 2022
- CALC 2011
- Country
- CVKD United States
- CALC United States
- Employees
- CVKD N/A
- CALC N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- CALC Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- CALC Health Care
- Exchange
- CVKD Nasdaq
- CALC Nasdaq
- Market Cap
- CVKD 29.5M
- CALC 26.7M
- IPO Year
- CVKD 2023
- CALC N/A
- Fundamental
- Price
- CVKD $12.32
- CALC $1.67
- Analyst Decision
- CVKD Strong Buy
- CALC Strong Buy
- Analyst Count
- CVKD 1
- CALC 3
- Target Price
- CVKD $32.00
- CALC $16.33
- AVG Volume (30 Days)
- CVKD 20.0K
- CALC 16.3K
- Earning Date
- CVKD 08-06-2025
- CALC 08-11-2025
- Dividend Yield
- CVKD N/A
- CALC N/A
- EPS Growth
- CVKD N/A
- CALC N/A
- EPS
- CVKD N/A
- CALC N/A
- Revenue
- CVKD N/A
- CALC N/A
- Revenue This Year
- CVKD N/A
- CALC N/A
- Revenue Next Year
- CVKD N/A
- CALC N/A
- P/E Ratio
- CVKD N/A
- CALC N/A
- Revenue Growth
- CVKD N/A
- CALC N/A
- 52 Week Low
- CVKD $5.70
- CALC $1.43
- 52 Week High
- CVKD $22.90
- CALC $5.97
- Technical
- Relative Strength Index (RSI)
- CVKD 38.54
- CALC 45.93
- Support Level
- CVKD $13.12
- CALC $1.68
- Resistance Level
- CVKD $15.99
- CALC $1.79
- Average True Range (ATR)
- CVKD 0.76
- CALC 0.08
- MACD
- CVKD -0.08
- CALC -0.00
- Stochastic Oscillator
- CVKD 6.45
- CALC 34.48
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.